Fleximer statistics

You need an account to access this content

info

Citations per year

Citations chart
info

Popular tool citations

chevron_left Alignment-free transcript quantification chevron_right
Popular tools chart
info

Tool usage distribution map

Tool usage distribution map
info

Associated diseases

Associated diseases

Fleximer specifications

Information


Unique identifier OMICS_25170
Name Fleximer
Software type Application/Script
Interface Command line interface
Restrictions to use None
Input data A predefined partition of transcriptome or a RNA-Seq data.
Input format FASTA
Output data A desired read length or a read count.
Operating system Unix/Linux
Programming languages C++
Computer skills Advanced
Stability Stable
Maintained Yes

Download


Versioning


Add your version

Maintainer


  • person_outline Chelsea Ju <>

Publication for Fleximer

Fleximer in publications

 (6)
PMCID: 5890575
PMID: 29534608
DOI: 10.1177/2040206618761299

[…] that has been shown to impart significant activity to the nucleoside scaffold as well as to allow it to overcome resistance related to point mutations.– the most recent series combined the fleximer approach with the acyclic nucleoside acyclovir, an fda approved drug for herpes virus. while these analogs inhibited the aforementioned viruses, acyclovir shows no activity […]

PMCID: 5890542
PMID: 29466861
DOI: 10.1177/2040206618756788

[…] binding site, particularly when faced with an electronic or steric interference. since point mutations typically involve these sorts of amino acid changes, we also hypothesized this would allow the fleximer to adjust and engage a secondary amino acid residue not previously involved in the mechanism of action. this would in turn allow it to retain its activity, something a rigid analogue would […]

PMCID: 4966842
PMID: 26909869
DOI: 10.1080/19420862.2016.1153211

[…] special adc track, which focused on improving adc properties, widening therapeutic windows or maximizing potencies., timothy lowinger (mersana) discussed advancing the dolaflexin platform and other fleximer-based adcs toward the clinic. the dolaflexin platform is the most advanced at mersana establishing a dar of ∼15 of a proprietary auristatin payload and using a fully biodegradable fleximer […]

PMCID: 5588531
PMID: 26679767
DOI: 10.1159/000443404

[…] prodrug of cpt (molecular weight: 70 kda), in which cpt is conjugated to a hydrophilic, biodegradable polyacetal polymer, poly(1-hydroxymethylethylene hydroxymethylformal), also known as phf or fleximer®, and is slowly released []. the recent advances with sn-38 (7-ethyl-10-hydroxy cpt: 12; fig. ) have been summarized in a recent review []. among the promising products developed […]

PMCID: 3929441
PMID: 24423618
DOI: 10.4161/mabs.27437

[…] the session with a discussion of a contract manufacturing approach to bring an adc from the lab to the clinic and ultimately to the market., tim lowinger (mersana therapeutics) presented the fleximer platforms, which consist of a clinically-validated biodegradable polymer, with a broad array of customizable linker chemistries (conjugation to lysine or cysteine) matched to therapeutic […]

Fleximer institution(s)
Department of Computer Science, University of California, Los Angeles, CA, USA

Fleximer reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review Fleximer